Clinical Trial

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

Study acronym: EMERALD-1
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people with Stage 2 or 3 neurotrophic keratitis (NK) via topical application. This is a Phase 1/2, multicenter, double-masked, placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of KB801 in these subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-23.
Trial Details
NCT Number NCT06999733
Lead Sponsor Krystal Biotech, Inc.
Conditions Neurotrophic Keratitis
Enrollment 60 participants
Start Date 2025-07-07
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-27